表紙:統合失調症治療薬の世界市場:2021年~2028年
市場調査レポート
商品コード
977298

統合失調症治療薬の世界市場:2021年~2028年

Global Schizophrenia Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
統合失調症治療薬の世界市場:2021年~2028年
出版日: 2021年07月12日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の統合失調症治療薬市場の成長は、治療を求める患者数の増加によって牽引され、医療インフラの改善に対する需要の急増が市場を促進すると予想されています。

当レポートでは、世界の統合失調症治療薬市場について調査分析し、業界分析、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 世界の統合失調症治療薬市場:調査手法と範囲

第2章 世界の統合失調症治療薬市場:市場定義と概要

第3章 世界の統合失調症治療薬市場:エグゼクティブサマリー

第4章 世界の統合失調症治療薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第5章 世界の統合失調症治療薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の統合失調症治療薬市場:COVID-19の分析

  • 市場に対するCOVID-19の分析
  • COVID-19における価格の動向
  • 需給スペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の統合失調症治療薬市場:薬剤分類別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:薬剤分類セグメント別
  • 市場魅力指数:薬剤分類セグメント別
    • 第一世代抗精神病薬
    • 第二世代抗精神病薬
    • 第三世代抗精神病薬
    • その他

第8章 世界の統合失調症治療薬市場:投与経路別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:投与経路別
  • 市場魅力指数:投与経路別
    • 経口
    • 注射

第9章 世界の統合失調症治療薬市場:流通チャネル別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:流通チャネルセグメント別
  • 市場魅力指数:流通チャネルセグメント別
    • 病院薬局
    • 薬局
    • その他

第10章 世界の統合失調症治療薬市場:地域別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:地域別
  • 市場魅力指数:地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋地域
  • 中東・アフリカ

第11章 世界の統合失調症治療薬市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • M&A分析

第12章 世界の統合失調症治療薬市場:企業プロファイル

  • Johnson & Johnson
  • Bristol-Myers Squibb/Otsuka Pharma
  • AstraZeneca
  • Sumitomo Dainippon
  • Eli Lilly
  • Alkermes
  • Vanda Pharma
  • Allergan
  • Pfizer.
  • anssen Global Services, LLC、など

第13章 世界の統合失調症治療薬市場:重要考察

第14章 世界の統合失調症治療薬市場:DataM

目次
Product Code: DMPH2901

Market Overview

The global schizophrenia drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling. People with schizophrenia require lifelong treatment.

Market Dynamics

The global schizophrenia drug growth is driven by the increase in the number of patients seeking treatment, and rising demand for improved healthcare infrastructure is expected to drive the market. The schizophrenia market remains replete with strong unmet needs. There is a need for innovation for the treatment of this debilitating disorder.

The increase in the number of patients taking treatment, is expected to drive the growth in the forecast period

Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. According to the World Health Organization 2019 report, the disease affects 20 million people worldwide. Furthermore, this number is likely to continue to increase, along with the aging population's growth. The increase in the number of patients taking treatment and the rising demand for improved healthcare infrastructure are expected to drive the market. In recent years, the government in several countries has collaborated well with many hospitals across nations to protect people from schizophrenia. The rising burden of the disease and the increasing need to manage it effectively drive the market's growth.

Rising awareness about mental disorders expected to drive the market growth

The increasing cases of mental disorders such as schizophrenia will uplift the global Schizophrenia Drugs Market shares. The surge in medical interventions for treating major mental disorders will enable growth in the global schizophrenia drugs market during the forecast period. Furthermore, the rising emphasis on mental illness and mental health in emerging nations will boost the global Schizophrenia Drugs Market revenue during the forecast period. Moreover, the increasing efficacy and safety features of treatment for schizophrenia will fuel demand among patients, which will accelerate the growth of the global schizophrenia drugs. Schizophrenia is diagnosed 1.4 times more frequently in males than females, as the onset is earlier in men. The peak age of onset is 20-28 years for males and 25-32 years for females.

Pipeline Analysis

Currently, 20 products are undergoing clinical trials for the treatment of schizophrenia. Some drugs are expected to aim at new molecular targets for treating unmet needs associated with the disorder. Several market players are expected to serve the unmet market needs, identify new targets, and consequentially develop stronger drug pipelines.

Results from clinical trials of these drugs reported positive top-line primary and secondary endpoint data. Apart from the typical serotonin and dopamine receptors, the drugs are expected to provide novel mechanisms for the treatment of schizophrenia..

Major side effects of drugs is likely to hinder the market growth

However, side effects include bladder disturbances, dermatologic allergic reactions, increased photosensitivity, inhibition of ejaculation, blurred vision, skin pigmentation, ocular opacities, mild fever, nasal congestion, increase in appetite, weight gain, engorgement of the breast with lactation, and menstrual irregularity in female patients. These factors are restricting the growth of the market in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic may have a profound effect on mental health. Those with schizophrenia will affect most. Patients are at higher risk of getting the COVID-19 virus; if being contaminated, what is the expected mortality rate in this patient group? What is the likelihood of suffering from a psychotic relapse due to the situation? According to their findings, schizophrenia patients are at greater infection risk due to their difficulties in following safety procedures. However, schizophrenia patients have deficits in applying adequate hygiene practices mainly because of impaired judgment and self-care.

Approximately 70% of schizophrenia patients suffer from one or more concomitant diseases, and 50-90% of them are regular smokers. Moreover, higher odds of pneumonia and mortality due to immunodeficiency have been suggested in several articles, alongside impaired lung function indications. Regarding the chance of relapse, the COVID-19 can indeed lead indirectly to relapse. These factors are driving the growth of the market in the forecast period.

Segment Analysis

The second-generation antipsychotics segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The usual first-line treatment for schizophrenia is an antipsychotic medication. One of the commonly preferred medications is risperidone, also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, in the United States, the Food and Drug Administration (FDA) approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of the bipolar disorder, and irritability associated with autistic disorders. There are several second-generation drugs available in the market, which are commonly proposed by doctors/physicians. The government's continuous support to private and public healthcare companies also boosts companies' growth in this segment. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.

The hospital pharmacy is expected to dominate the schizophrenia drugs during the forecast period

The hospital pharmacies held the largest share in the schizophrenia drugs market. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global schizophrenia drugs

North America region is dominating the global schizophrenia drugs accounted for the largest market share in 2020. The United States accounted for the largest market share in North America region. A major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care for early treatment capabilities and government involvement in increasing healthcare expenditure. This factor is driving the market growth in the forecast period.

Competitive Landscape

The schizophrenia drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, and Pfizer. Johnson & Johnson, Otsuka, and Lundbeck among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the schizophrenia drugs globally.

Schizophrenia Drugs Market Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the schizophrenia drugs segmentation by drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in schizophrenia drugs by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of schizophrenia drugs - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global schizophrenia drugs report would provide an access to an approx. 61 market data table, 52 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Schizophrenia Drugs Market - By Drug Class

  • First-Generation Antipsychotics
  • Second-generation Antipsychotics

(Risperdal (Risperidone)

Invega (Paliperidone)

Zyprexa (Olanzapine)

Geodon (Ziprasidone)

Seroquel (Quetiapine)

Latuda (Lurasidone)

Aristada (Aripiprazole lauroxil)

Fanapt (Iloperidone)

Saphris (Asenapine)

Vraylar (Cariprazine)

  • Third-generation Antipsychotics

(Abilify (Aripiprazole)

  • Generics
  • Other

Global Schizophrenia Drugs Market -By Route of Administration

  • Oral Antipsychotics
  • Injectable Antipsychotics

Global Schizophrenia Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Schizophrenia Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Schizophrenia Drugs Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Schizophrenia Drugs - Market Definition and Overview

3. Global Schizophrenia Drugs - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Schizophrenia Drugs - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Burden of Schizophrenia and Associated Disorders
      • 4.1.1.2. Increasing Investments in R&D
    • 4.1.2. Restraints:
      • 4.1.2.1. Increase in Cases of Addiction Associated with these Drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Schizophrenia Drugs - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Local Anesthesia Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Schizophrenia Drugs - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. First Generation Antipsychotics Introduction*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Second-generation Antipsychotics
    • 7.3.1. Risperdal (Risperidone)
    • 7.3.2. Invega (Paliperidone)
    • 7.3.3. Zyprexa (Olanzapine)
    • 7.3.4. Geodon (Ziprasidone)
    • 7.3.5. Seroquel (Quetiapine)
    • 7.3.6. Latuda (Lurasidone)
    • 7.3.7. Aristada (Aripiprazole Lauroxil)
    • 7.3.8. Fanapt (Iloperidone)
    • 7.3.9. Saphris (Asenapine)
    • 7.3.10. Vraylar (Cariprazine)
  • 7.4. Third-generation Antipsychotics
    • 7.4.1. Abilify (Aripiprazole)
  • 7.5. Generics
  • 7.6. Others

8. Global Schizophrenia Drugs - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral Antipsychotics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Injectable Antipsychotics

9. Global Schizophrenia Drugs - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Schizophrenia Drugs - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.3. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Schizophrenia Drugs - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Schizophrenia Drugs - Company Profiles

  • 12.1. Johnson & Johnson *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb/ Otsuka Pharma
  • 12.3. AstraZeneca
  • 12.4. Sumitomo Dainippon
  • 12.5. Eli Lilly
  • 12.6. Alkermes
  • 12.7. Vanda Pharma
  • 12.8. Allergan
  • 12.9. Pfizer.
  • 12.10. Janssen Global Services, LLC

LIST NOT EXHAUSTIVE

13. Global Schizophrenia Drugs - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us